CURRICULUM VITAE Part I General Information DATE PREPARED ...

61. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J,
Boehm JS, Dobson J, Urashima M, McHenry K, Pinchback R, Ligon AH, Cho J, Haery L,
Greulich H, Reich M, Winckler W, Weir BA, Tanaka K, Chiang DY, Bass AJ, Loo A,
Hoffman C, Prensner J, Liefeld T, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H,
Tepper JE, Fletcher JA, Baselga J, Tsao M, Rubin MA, Janne PA, Daly MJ, Nucera C,
Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway
LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Lander ES, Getz G,
Golub TR, Sellers WR, Meyerson M. The landscape of copy number alterations across
multiple human cancers. Nature. 2010;463:899-905.
62. Choueiri TK, Regan MM, Rosenberg JE, Oh WK, Clement J, Amato AM, McDermott D,
Cho DC, Atkins MB, Signoretti S. Carbonic anhydrase IX (CAIX) and pathologic features
as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving
VEGF-targeted therapy. BJU Int. 2010;106(6):772-8.
63. Lee SH, Poulogiannis G, Pyne S, Jia S, Zou L, Signoretti S, Loda M, Cantley LC, and
Roberts TM. A constitutively activated form of the p110β isoform of PI3-kinase induces
prostatic intraepithelial neoplasia in mice. Proc Natl Acad Sci (U S A). 2010;107(24):11002-
7.
64. Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB, Signoretti S,
Mier JW. The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235
Compared to Rapamycin in Renal Cell Carcinoma. Clin Cancer Res. 2010;16(14):3628-38.
65. Yang W, Ahmed M, Elian M, Hady ES, Levchenko TS, Sawant RR, Signoretti S, Collins M,
Torchilin VP, Goldberg SN. Do Liposomal Apoptotic Enhancers IncreaseTumor Coagulation
and End-Point Survival in Percutaneous Radiofrequency Ablation of Tumors in a Rat Tumor
Model? Radiology 2010 Sep 21. [Epub ahead of print].
66. Genega, EM, Ghebremichael, M, Najarian R, Fu Y, Wang, Y, Argani, P, Grisanzio, C,
Signoretti S. CAIX Expression in Renal Neoplasms: Correlation with Tumor Type and
Grade. Am J Clin Pathol. 2010;134(6):873-9.
67. Bhatt R, Wang X, Zhang L, Collins M, Signoretti S, Alsop D, Goldberg SN, Atkins MB,
Mier JW. Renal cancer resistance to antiangiogenic therapy is delayed by restoration of
angiostatic signaling. Mol Cancer Ther. 2010:9(10):2793-802.
68. Moslehi J, Minamishima YA, Padera RF, Signoretti S, Liao R, and Kaelin WG. Loss of
PHD Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic
Cardiomyopathy. Circulation. 2010;122(10):1004-16.
69. Gan B, Lim C, Chu G, Hua S, Ding Z,Collins M, Hu J, Jiang S, Fletcher-Sananikone E,
Zhuang L, Chang M, Zheng H, Wang YA, Kwiatkowski DJ, Kaelin WG, Signoretti S and
DePinho RA. FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal
tumorigenesis. Cancer Cell. 2010;18(5):472-84.
70. Ding Z, Wu C, Chu GC, Xiao Y, Ho D, Zhang J, Perry SR, Labrot ES, Wu X, Lis R, Hoshida
Y, Hiller D, Hu B, Jiang S, Zheng H, Stegh AH, Scott AL, Signoretti S, El-Bardeesy NM,
Wang YA, Hill D, Golub TR, Stampfer MJ, Wong WH, Loda M, Mucci L, Chin L &
DePinho RA. SMAD4-dependent barrier constrains prostate cancer growth and metastatic
progression. Nature. 2011;470(7333):269-73.
16